134 F. Supp. 3d 820
D.N.J.2015Background
- Plaintiffs (three pediatric practices) challenge Sanofi Pasteur’s loyalty "bundle" that tied Menactra (MCV4) purchases to discounts on other pediatric vaccines after Novartis planned Menveo entry in 2009.
- Sanofi allegedly offered steep loyalty discounts to customers buying a specified share of four pediatric vaccines; non‑compliant buyers paid substantially higher prices. Prices for MCV4 rose after Novartis entered.
- Plaintiffs seek certification of a nationwide direct‑purchaser class of Menactra purchasers (Mar 1, 2010 through the end of the injury period), excluding governmental purchasers and certain affiliates. Approximately 26,000 class members.
- Plaintiffs’ damages/causation expert is Prof. Einer Elhauge, who (1) defines relevant markets, (2) opines the bundle was exclusionary (a "penalty"), (3) finds the bundle split the market into "Sanofi‑loyal" and "disloyal" customers using documents and regressions, and (4) uses a differentiated Bertrand model to estimate but‑for prices and classwide overcharge. Defendant’s rebuttal expert is David Kaplan.
- Court held a Daubert hearing, denied Sanofi’s motion to exclude Elhauge, and granted class certification under Rule 23(b)(3), finding commonality, predominance, adequacy, and a workable classwide damages methodology.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Admissibility of Elhauge’s opinions under Daubert/Rule 702 | Elhauge is qualified; uses documents, economic literature, regressions, and a differentiated Bertrand model to show market division, price impact, and classwide injury. | Kaplan and Sanofi say regressions omit variables, have low R2, are sensitive to inputs; Bertrand model is mis‑specified (one‑shot game, not calibrated), ignores VFC floor and costs; across‑the‑board overcharge assumption is unwarranted. | Court denied the motion to exclude. It found Elhauge qualified and his methods sufficiently reliable and fit the class certification tasks; many challenges went to weight, not admissibility. |
| Market definition and monopoly power | Markets defined (DTaP, IPV, HIB, MCV4); Sanofi held monopoly/dominant shares in relevant markets. | No meaningful dispute over market definitions in this opinion. | Court accepted Elhauge’s market definitions and findings of monopoly power for class certification. |
| Antitrust liability (bundling as exclusionary conduct) | Bundle was a penalty (not procompetitive), divided the MCV4 market, foreclosed a substantial portion from Novartis, and thereby inflated prices classwide. | Sanofi contends bundle did not meaningfully foreclose competition; Novartis gained some share; market may be coordinated or other factors explain pricing. | Court concluded plaintiffs presented common evidence of willful maintenance of monopoly via exclusionary bundling sufficient for class certification—foreclosure need not be total. |
| Predominance & damages methodology | Common proof (documents + Elhauge’s model/regressions) shows classwide impact; differentiated Bertrand model yields a classwide overcharge (approx. 32% for Menactra) that can be applied to aggregate sales. | Sanofi argues individualized issues (price discrimination, VFC purchases, variable discounts) defeat predominance and make damages non‑classwide. | Court found common questions predominate, the damages model is a permissible classwide ‘‘reasonable estimate,’’ and a class action is superior to individual suits. |
Key Cases Cited
- Daubert v. Merrell Dow Pharm., 509 U.S. 579 (court acts as gatekeeper for expert admissibility)
- Kumho Tire Co. v. Carmichael, 526 U.S. 137 (Daubert standard applies to all expert testimony)
- Wal‑Mart Stores, Inc. v. Dukes, 564 U.S. 338 (plaintiff must demonstrate Rule 23 requirements)
- Comcast Corp. v. Behrend, 569 U.S. 27 (class certification requires a damages model consistent with liability)
- In re Linerboard Antitrust Litig., 305 F.3d 145 (use of economic modeling plus price‑structure evidence to show classwide impact)
- LePage’s Inc. v. 3M, 324 F.3d 141 (exclusionary bundling and leveraging monopoly power doctrines)
- United States v. Dentsply Int’l, Inc., 399 F.3d 181 (foreclosure analysis: not total foreclosure but substantial restriction)
- Brooke Group Ltd. v. Brown & Williamson Tobacco Corp., 509 U.S. 209 (distinguishing list vs. net price evidence in predatory pricing contexts)
- Zenith Radio Corp. v. Hazeltine Research, 395 U.S. 100 (overcharge establishes antitrust injury for direct purchasers)